Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of B.1.617 and RBD SARS-CoV-2 variants on vaccine efficacy: An in-silico approach.

Indian journal of medical microbiology - 1 Jan 2000

Ranjan Prashant, Neha, Devi Chandra, Jain Garima, Mallick Chandana Basu, Das Parimal

Abstract excerpt

PURPOSE: The existing panels of COVID-19 vaccines are based on the spike protein of an earlier SARS-CoV-2 strain that emerged in Wuhan, China. However, the evolving nature of SARS-CoV-2 has resulted in the emergence of new variants, thereby posing a greater challenge in the management of the disease. India faced a deadlier second wave of infections very recently, and genomic surveillance revealed that the B.1.617...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Neutralizing

Share to COVID-19

Share to COVID-19 Vaccines

Share to Molecular Dynamics Simulation

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 35370005
DOI: 10.1016/j.ijmmb.2022.03.009
PMCID: PMC8971047

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of B.1.617 and RBD SARS-CoV-2 variants on vaccine efficacy: An in-silico approach.PMID 35370005Read ↗

Impact of B.1.617 and RBD SARS-CoV-2 Variants on Vaccine Efficacy: An In-silico ApproachSemantic proximity Read ↗

Structural evolution of Delta lineage of SARS-CoV-2.Semantic proximity Read ↗

E156G and Arg158, Phe-157/del mutation in NTD of spike protein in B.1.617.2 lineage of SARS-CoV-2 leads to immune evasion through antibody escapeSemantic proximity Read ↗

Structural basis of Omicron immune evasion: A comparative computational study of Spike protein-Antibody interactionSemantic proximity Read ↗

D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity.Semantic proximity Read ↗

Molecular Insights into the Variability in Infection and Immune Evasion Capabilities of SARS-CoV-2 Variants: A Sequence and Structural Investigation of the RBD Domain.Semantic proximity Read ↗

Preliminary Structural Data Revealed That the SARS‐CoV‐2 B.1.617 Variant's RBD Binds to ACE2 Receptor Stronger Than the Wild Type to Enhance the InfectivitySemantic proximity Read ↗

Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.Semantic proximity Read ↗

Comparative structural analyses of selected spike protein-RBD mutations in SARS-CoV-2 lineages.Semantic proximity Read ↗

The SARS-CoV-2 B.1.618 variant slightly alters the spike RBD–ACE2 binding affinity and is an antibody escaping variant: a computational structural perspectiveSemantic proximity Read ↗

Comparative Structural Analyses of Selected Spike Protein-RBD Mutations in SARS-CoV-2 LineagesSemantic proximity Read ↗

Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.